SYRE - Spyre Therapeutics Inc.
IEX Last Trade
28.78
0.710 2.467%
Share volume: 411,564
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$28.07
0.71
2.53%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-03 | 2023-03-02 | 2023-05-11 | 2023-08-11 | 2023-11-09 | 2024-02-29 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 106.707 M | 91.566 M | 71.144 M | 52.453 M | 243.529 M | 207.265 M | 341.859 M | 487.602 M | |
| Current Assets | 96.646 M | 82.219 M | 62.258 M | 44.375 M | 239.886 M | 205.949 M | 341.528 M | 487.273 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 7.617 M | 7.874 M | 6.172 M | 5.567 M | 2.882 M | 2.187 M | 2.251 M | 2.632 M | |
| Short Term Investments | 7.617 M | 7.874 M | 6.172 M | 5.567 M | 2.882 M | 2.187 M | 2.251 M | 2.632 M | |
| Total Receivables | 479.000 K | 669.000 K | 375.000 K | 330.000 K | 1.646 M | 163.000 K | 0.000 | 0.000 | |
| Current Cash | 88.550 M | 73.676 M | 55.711 M | 38.478 M | 235.358 M | 203.599 M | 339.277 M | 484.641 M | |
| Total Non-current Assets | 10.061 M | 9.347 M | 8.886 M | 8.078 M | 3.643 M | 1.316 M | 331.000 K | 329.000 K | |
| Property Plant Equipment | 3.890 M | 3.555 M | 3.220 M | 3.424 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 4.367 M | 4.263 M | 4.113 M | 3.344 M | 2.326 M | 9.000 K | 9.000 K | 10.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 106.707 M | 91.566 M | 71.144 M | 52.453 M | 243.529 M | 207.265 M | 341.859 M | 487.602 M | |
| Total liabilities | 22.550 M | 24.011 M | 20.839 M | 18.801 M | 253.575 M | 65.562 M | 157.843 M | 335.333 M | |
| Total current liabilities | 15.862 M | 17.678 M | 14.656 M | 12.637 M | 232.234 M | 44.872 M | 31.978 M | 42.818 M | |
| Accounts Payable | 1.958 M | 4.178 M | 677.000 K | 2.062 M | 23.664 M | 21.501 M | 896.000 K | 18.634 M | |
| Other liabilities | 2.372 M | 2.174 M | 2.179 M | 2.341 M | 21.341 M | 20.690 M | 41.310 M | 39.110 M | |
| Current long term debt | 477.000 K | 587.000 K | 625.000 K | 608.000 K | 4.331 M | 0.000 | 0.000 | 0.000 | |
| Long term debt | 4.316 M | 4.159 M | 4.004 M | 3.823 M | 0.000 | 0.000 | 84.555 M | 253.405 M | |
| Other liabilities | 2.372 M | 2.174 M | 2.179 M | 2.341 M | 21.341 M | 20.690 M | 41.310 M | 39.110 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 84.157 M | 67.555 M | 50.305 M | 33.652 M | -10.046 M | 141.703 M | 184.016 M | 152.269 M | |
| Common stock | 3.288 M | 3.768 M | 3.789 M | 3.771 M | 3.823 M | 4.294 M | 15.701 M | 36.513 M | |
| Retained earnings | -388.568 M | -406.802 M | -425.624 M | -444.046 M | -661.127 M | -701.234 M | -764.414 M | -808.271 M |